Prevalence and Characteristics of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome

Apridonidze, Teimuraz; Essah, Paulina A.; Iuorno, Maria J.; Nestler, John E.

doi:10.1210/jc.2004-1045

Cited by 931Ovarian function and disordersDiabetes, Cardiovascular Risks, and LipoproteinsGenetic and Kidney Cyst Diseases

Prevalence and Characteristics of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome

Apridonidze, Teimuraz, Essah, Paulina A., Iuorno, Maria J., Nestler, John E.·2005·The Journal of Clinical Endocrinology & Metabolism

DOI 10.1210/jc.2004-1045

Open this paper in CoChat — free account

Abstract

The polycystic ovary syndrome (PCOS) is characterized by insulin resistance with compensatory hyperinsulinemia. Insulin resistance also plays a role in the metabolic syndrome (MBS). We hypothesized that the MBS is prevalent in PCOS and that women with both conditions would present with more hyperandrogenism and menstrual cycle irregularity than women with PCOS only. We conducted a retrospective chart review of all women with PCOS seen over a 3-yr period at an endocrinology clinic. Of the 161 PCOS cases reviewed, 106 met the inclusion criteria. The women were divided into two groups: 1) women with PCOS and the MBS (n = 46); and 2) women with PCOS lacking the MBS (n = 60). Prevalence of the MBS was 43%, nearly 2-fold higher than that reported for age-matched women in the general population. Women with PCOS had persistently higher prevalence rates of the MBS than women in the general population, regardless of matched age and body mass index ranges. Acanthosis nigricans was more frequent in women with PCOS and the MBS. Women with PCOS and the MBS had significantly higher levels of serum free testosterone (P = 0.002) and lower levels of serum SHBG (P = 0.001) than women with PCOS without the MBS. No differences in total testosterone were observed between the groups. We conclude that the MBS and its components are common in women with PCOS, placing them at increased risk for cardiovascular disease. Women with PCOS and the MBS differ from their counterparts lacking the MBS in terms of increased hyperandrogenemia, lower serum SHBG, and higher prevalence of acanthosis nigricans, all features that may reflect more severe insulin resistance.

Integrity signals

Registry

Crossref · 10.1210/jc.2004-1045

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Insulin resistance and the metabolic syndrome are associated with several other conditions, including fatty liver, polycystic ovary syndrome, cholesterol gallstones, sleep apnea, lipodystrophies, and protease-inhibitor therapy for HIV.
“Finally, insulin resistance and the metabolic syndrome are associated with a variety of other conditions [75][76][77] ; some of these are fatty liver, 30,78 polycystic ovary syndrome, 79 cholesterol gallstones, 80 sleep apnea, 81 lipodystrophies, 82 and protease-inhibitor therapy for HIV.83”
From Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement (2005) · cites this paper as [79]
Women with PCOS have an increased prevalence of metabolic syndrome, which is associated with an increased risk for DM2 and CVD.
“Women with PCOS also have an increased prevalence of metabolic syndrome (associated with an increased risk for DM2 and CVD), 28”
From Assessment and management of polycystic ovary syndrome: Summary of an evidence-based guideline (2011) · cites this paper as [28]

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
(2002) · Circulation · doi:10.1161/circ.106.25.3143 · Cited by 14,092 · see citing works
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198 · see citing works
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154 · see citing works
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,320 · see citing works
Prevalence of the Metabolic Syndrome Among US Adults: Findings From the Third National Health and Nutrition Examination Survey
Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698 · see citing works
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220 · see citing works
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760 · see citing works
Follow-up report on the diagnosis of diabetes mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3160 · Cited by 3,784 · see citing works
Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis
Dunaif, A. E. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.6.0318 · Cited by 2,761 · see citing works
Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994
Harris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703 · see citing works
Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743 · see citing works
Prevalence of the Polycystic Ovary Syndrome in Unselected Black and White Women of the Southeastern United States: A Prospective Study1
Knochenhauer, E. S., Key, T. J., Kahsar-Miller, M., Waggoner, W., Boots, L. R., & Azziz, R. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.9.5090 · Cited by 1,568 · see citing works
High-Density Lipoprotein — The Clinical Implications of Recent Studies
Desforges, J. F., Gordon, D. J., & Rifkind, B. M. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911093211907 · Cited by 1,547 · see citing works
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257 · see citing works
Prospective Analysis of The Insulin-Resistance Syndrome (Syndrome X)
Haffner, S. M., Valdez, R. A., Hazuda, H. P., Mitchell, B. D., Morales, P. A., & D, M. P. S. M. (1992) · Diabetes · doi:10.2337/diab.41.6.715 · Cited by 1,234 · see citing works
Prevalence of the Polycystic Ovary Syndrome in Unselected Black and White Women of the Southeastern United States: A Prospective Study
Knochenhauer, E. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.9.3078 · Cited by 1,134 · see citing works
Obesity and the polycystic ovary syndrome
Gambineri, A., Pelusi, C., Vicennati, V., Pagotto, U., & Pasquali, R. (2002) · International Journal of Obesity · doi:10.1038/sj.ijo.0801994 · Cited by 838 · see citing works
Risk Factors for Coronary Artery Disease in Healthy Persons with Hyperinsulinemia and Normal Glucose Tolerance
Zavaroni, I., Bonora, E., Pagliara, M., Dall’Aglio, E., Luchetti, L., Buonanno, G., Bonati, P. A., Bergonzani, M., Gnudi, L., Passeri, M., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198903163201105 · Cited by 770 · see citing works
Decreases in Ovarian Cytochrome P450c17α Activity and Serum Free Testosterone after Reduction of Insulin Secretion in Polycystic Ovary Syndrome
Nestler, J. E., & Jakubowicz, D. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350902 · Cited by 743 · see citing works
Self-citation
High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase
Yuhanna, I. S., Zhu, Y., Cox, B. E., Hahner, L., Osborne-Lawrence, S. L., Lu, P., Marcel, Y. L., Anderson, R. G. W., Mendelsohn, M. E., Hobbs, H. H., et al. (2001) · Nature Medicine · doi:10.1038/89986 · Cited by 742 · see citing works
Insulin resistance in nonobese patients with polycystic ovarian disease
CHANG, R. J., NAKAMURA, R. M., JUDD, H. L., & KAPLAN, S. A. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-57-2-356 · Cited by 704 · see citing works
HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3
Nofer, J., van der Giet, M., Tölle, M., Wolinska, I., Lipinski, K. V. W., Baba, H. A., Tietge, U. J. F., Gödecke, A., Ishii, I., Kleuser, B., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci18004 · Cited by 694 · see citing works
A Comparison of the Prevalence of the Metabolic Syndrome Using Two Proposed Definitions
Ford, E. S., & Giles, W. H. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.575 · Cited by 616 · see citing works
Hypertriglyceridemia, insulin resistance, and the metabolic syndrome
Grundy, S. M. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00211-8 · Cited by 610 · see citing works
HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3
Nofer, J., van der Giet, M., Tölle, M., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200418004 · Cited by 607 · see citing works
Polycystic ovary syndrome and risk for myocardial infarction: Evaluated from a risk factor model based on a prospective population study of women
Dahlgren, E., Janson, P. O., Johansson, S., Lapidus, L., & Odén, A. (1992) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.3109/00016349209006227 · Cited by 544 · see citing works
Evidence for Distinctive and Intrinsic Defects in Insulin Action in Polycystic Ovary Syndrome
Dunaif, A. E., Segal, K. R., Shelley, D., Green, G., Dobrjansky, A., & Licholai, T. (1992) · Diabetes · doi:10.2337/diab.41.10.1257 · Cited by 544 · see citing works
Prevalence and Characteristics of the Metabolic Syndrome in the San Antonio Heart and Framingham Offspring Studies
Meigs, J. B., Wilson, P. W. F., Nathan, D. M., D’Agostino, R. B., Williams, K., & Haffner, S. M. (2003) · Diabetes · doi:10.2337/diabetes.52.8.2160 · Cited by 464 · see citing works
Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome
Glueck, C. J., Papanna, R., Wang, P., Goldenberg, N., & Sieve-Smith, L. (2003) · Metabolism · doi:10.1016/s0026-0495(03)00104-5 · Cited by 396 · see citing works
Syndrome X and Mortality: A Population-based Study
Trevisan, M., Liu, J., Bahsas, F. B., & Menotti, A. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009572 · Cited by 389 · see citing works
Cellular mechanisms of insulin resistance in polycystic ovarian syndrome
Ciaraldi, T. P. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.2.577 · Cited by 336 · see citing works
Insulin-Like Growth Factor I and Insulin Potentiate Luteinizing Hormone-Induced Androgen Synthesis by Rat Ovarian Thecal-Interstitial Cells*
Cara, J. F., & Rosenfield, R. L. (1988) · Endocrinology · doi:10.1210/endo-123-2-733 · Cited by 333 · see citing works
Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: A common endocrinopathy with distinct pathophysiologic features
Barbieri, R. L., & Ryan, K. J. (1983) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(83)90091-1 · Cited by 295 · see citing works
Insulin Resistance, Hyperinsulinemia, Hypertriglyceridemia, and Hypertension: Parallels Between Human Disease and Rodent Models
Reaven, G. M. (1991) · Diabetes Care · doi:10.2337/diacare.14.3.195 · Cited by 287 · see citing works
Hyperandrogenic anovulation (PCOS): A unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus
Dunaif, A. E. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80057-6 · Cited by 235 · see citing works
High Density Lipoprotein Binding to Scavenger Receptor, Class B, Type I Activates Endothelial Nitric-oxide Synthase in a Ceramide-dependent Manner
Li, X., Titlow, W. B., Jackson, B., Giltiay, N., Nikolova‐Karakashian, M., Uittenbogaard, A., & Smart, E. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110985200 · Cited by 162 · see citing works
The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycystic ovarian syndrome: implications for SHBG as a surrogate marker of insulin resistance.
Jayagopal, V., Kilpatrick, E. S., Jennings, P. E., Hepburn, D. A., & Atkin, S. L. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020557 · Cited by 137 · see citing works
Acanthosis Nigricans, Insulin Action, and Hyperandrogenism: Clinical, Histological, and Biochemical Findings*
Dunaif, A. E., Green, G., Phelps, R. G., Lebwohl, M., Futterweit, W., & LEWY, L. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-3-590 · Cited by 103 · see citing works
The androgenic sex hormone profile is an essential feature of metabolic syndrome in premenopausal women: a controlled community-based study
Korhonen, S., Hippeläinen, M., Vanhala, M. J., Heinonen, S. T., & NISKANEN, L. K. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(03)00347-9 · Cited by 101 · see citing works
Insulin-like growth factor-I enhances luteinizing hormone binding to rat ovarian theca-interstitial cells.
Cara, J. F., Fan, J., Azzarello, J. T., et al. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114745 · Cited by 80 · see citing works
The role of dual energy X-rayabsorptiometry of lumbar spine and proximal femur in the diagnosis and follow-up of osteoporosis
Rizzoli, R., Slosman, D. O., & Bonjour, J. ‐. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(05)80043-9 · Cited by 75 · see citing works
Low Insulin Sensitivity (Si = 0) in Diabetic and Nondiabetic Subjects in the Insulin Resistance Atherosclerosis Study
Haffner, S. M., D’Agostino, R., Festa, A., Bergman, R. N., Mykkänen, L. M., Karter, A. J., Saad, M. F., & Wagenknecht, L. E. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2796 · Cited by 61 · see citing works
Mediators of postreceptor action of insulin
Larner, J. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90653-8 · Cited by 41 · see citing works
Self-selected women with polycystic ovary syndrome are reproductively and metabolically abnormal and undertreated
Legro, R. S., Urbanek, M., Kunselman, A. R., Leiby, B. E., & Dunaif, A. E. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(02)03153-9 · Cited by 33 · see citing works
U.S. Department of Health and Human Services (DHHS)
J.Stahl, M. (2004) · Encyclopedia of Health Care Management · doi:10.4135/9781412950602.n826 · Cited by 13 · see citing works

Flagged first, then by citations

Sorted by citations

Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961 · see citing works
Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143 · see citing works
The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.06.035 · Cited by 2,132 · see citing works
Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group
Fauser, B. C. J. M., Tarlatzis, B. C., Rebar, R. W., Legro, R. S., Balen, A. H., Lobo, R., Carmina, E., Chang, J., Yildiz, B. O., Laven, J. S. E., et al. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.09.024 · Cited by 1,976 · see citing works
Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan
Teede, H., Deeks, A., & Moran, L. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-41 · Cited by 1,565 · see citing works
The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited
Rosenfield, R. L., & Ehrmann, D. A. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1104 · Cited by 1,603 · see citing works
Polycystic ovary syndrome: etiology, pathogenesis and diagnosis
Goodarzi, M. O., Dumesic, D. A., Chazenbalk, G., & Azziz, R. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.217 · Cited by 1,488 · see citing works
Impaired Glucose Tolerance, Type 2 Diabetes and Metabolic Syndrome in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis
Moran, L. J., Misso, M. L., Wild, R. A., & Norman, R. J. (2010) · Human Reproduction Update · doi:10.1093/humupd/dmq001 · Cited by 1,108 · see citing works
Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome
Dumesic, D. A., Oberfield, S. E., Stener-Victorin, E., Marshall, J. C., Laven, J. S., & Legro, R. S. (2015) · Endocrine Reviews · doi:10.1210/er.2015-1018 · Cited by 1,020 · see citing works
Assessment of Cardiovascular Risk and Prevention of Cardiovascular Disease in Women with the Polycystic Ovary Syndrome: A Consensus Statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society
Wild, R. A., Carmina, E., Diamanti-Kandarakis, E., Dokras, A., Escobar-Morreale, H. F., Futterweit, W., Lobo, R., Norman, R. J., Talbott, E., & Dumesic, D. A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2724 · Cited by 1,010 · see citing works
Prevalence and Predictors of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome
Ehrmann, D. A., Liljenquist, D. R., Kasza, K., Azziz, R., Legro, R. S., & Ghazzi, M. N. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1329 · Cited by 703 · see citing works
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
Tang, T., Lord, J. M., Norman, R. J., Yasmin, E., & Balen, A. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053.pub5 · Cited by 698 · see citing works
Lipid Levels in Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis
Wild, R. A., Rizzo, M., Clifton, S., & Carmina, E. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.12.027 · Cited by 477 · see citing works
Treatment of obesity in polycystic ovary syndrome: A position statement of the Androgen Excess and Polycystic Ovary Syndrome Society
Moran, L. J., Pasquali, R., Teede, H. J., Hoeger, K. M., & Norman, R. J. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.09.018 · Cited by 444 · see citing works
Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: A comprehensive review
Palomba, S., Falbo, A., Zullo, F., & Orio, F. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0030 · Cited by 426 · see citing works
Ethnicity, Obesity and the Prevalence of Impaired Glucose Tolerance and Type 2 Diabetes in PCOS: A Systematic Review and Meta-Regression
Kakoly, N. S., Khomami, M. B., Joham, A. E., Cooray, S. D., Misso, M. L., Norman, R. J., Harrison, C. L., Ranasinha, S., Teede, H. J., & Moran, L. J. (2018) · Human Reproduction Update · doi:10.1093/humupd/dmy007 · Cited by 384 · see citing works
Assessment and management of polycystic ovary syndrome: Summary of an evidence-based guideline
Teede, H. J., Misso, M. L., Deeks, A. A., Moran, L. J., Stuckey, B. G. A., Wong, J. L. A., Norman, R. J., Costello, M. F., & Groups, O. B. O. T. G. D. (2011) · Medical Journal of Australia · doi:10.5694/mja11.10915 · Cited by 379 · see citing works
Metabolic features of the reproductive phenotypes of polycystic ovary syndrome
Moran, L., & Teede, H. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp008 · Cited by 362 · see citing works
Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists
Cena, H., Chiovato, L., & Nappi, R. E. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa285 · Cited by 356 · see citing works
Testosterone, sex hormone-binding globulin and the metabolic syndrome: A systematic review and meta-analysis of observational studies
Brand, J. S., van der Tweel, I., Grobbee, D. E., Emmelot-Vonk, M. H., & van der Schouw, Y. T. (2011) · International Journal of Epidemiology · doi:10.1093/ije/dyq158 · Cited by 334 · see citing works
Metformin for the treatment of the polycystic ovary syndrome
Nestler, J. E. (2008) · New England Journal of Medicine · doi:10.1056/nejmct0707092 · Cited by 313 · see citing works
Self-citation
Deconstructing a Syndrome: Genomic Insights Into PCOS Causal Mechanisms and Classification
Dapas, M., & Dunaif, A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac001 · Cited by 300 · see citing works
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
Morley, L. C., Tang, T., Yasmin, E., Norman, R. J., & Balen, A. H. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053.pub6 · Cited by 296 · see citing works
Complications and challenges associated with polycystic ovary syndrome: current perspectives
Palomba, S., Santagni, S., Falbo, A., & La Sala, G. B. (2015) · International Journal of Women's Health · doi:10.2147/ijwh.s70314 · Cited by 287 · see citing works
Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome
Barber, T. M., Wass, J. A. H., McCarthy, M. I., & Franks, S. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02764.x · Cited by 254 · see citing works
Gender-specific care of the patient with diabetes: review and recommendations
Legato, M. J., Gelzer, A., Goland, R., Ebner, S. A., Rajan, S., Villagra, V., & Kosowski, M. (2006) · Gender Medicine · doi:10.1016/s1550-8579(06)80202-0 · Cited by 225 · see citing works
Metabolic Syndrome and PCOS: Pathogenesis and the Role of Metabolites
Chen, W., & Pang, Y. (2021) · Metabolites · doi:10.3390/metabo11120869 · Cited by 228 · see citing works
Insulin resistance and PCOS: chicken or egg?
Moghetti, P., & Tosi, F. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01351-0 · Cited by 209 · see citing works
Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome
Costello, M. F., Shrestha, B., Eden, J., Johnson, N., & Moran, L. J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005552.pub2 · Cited by 197 · see citing works
Depression, anxiety and cardiometabolic risk in polycystic ovary syndrome
Cinar, N., Kizilarslanoglu, M. C., Harmanci, A., Aksoy, D. Y., Bozdag, G., Demir, B., & Yildiz, B. O. (2011) · Human Reproduction · doi:10.1093/humrep/der338 · Cited by 168 · see citing works
Effect of Lifestyle Intervention on Features of Polycystic Ovarian Syndrome, Metabolic Syndrome, and Intima-Media Thickness in Obese Adolescent Girls
Lass, N., Kleber, M., Winkel, K., Wunsch, R., & Reinehr, T. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1609 · Cited by 160 · see citing works
Metabolic syndrome: Does it differ between women and men?
Rochlani, Y., Pothineni, N. V., & Mehta, J. L. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6593-6 · Cited by 152 · see citing works
Randomized comparison of the influence of dietary management and/or physical exercise on ovarian function and metabolic parameters in overweight women with polycystic ovary syndrome
Nybacka, Å., Carlström, K., Ståhle, A., Nyrén, S., Hellström, P. M., & Hirschberg, A. L. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.09.006 · Cited by 138 · see citing works
Racial and ethnic differences in the polycystic ovary syndrome metabolic phenotype
Engmann, L., Jin, S., Sun, F., Legro, R. S., Polotsky, A. J., Hansen, K. R., Coutifaris, C., Diamond, M. P., Eisenberg, E., Zhang, H., et al. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.01.003 · Cited by 144 · see citing works
Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome
Cussons, A. J., Watts, G. F., Burke, V., Shaw, J. E., Zimmet, P. Z., & Stuckey, B. G. A. (2008) · Human Reproduction · doi:10.1093/humrep/den263 · Cited by 140 · see citing works
Metabolic diseases and associated complications: sex and gender matter
Kautzky‐Willer, A., & Handisurya, A. (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2009.02161.x · Cited by 138 · see citing works
Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria
Goverde, A. J., van Koert, A. J. B., Eijkemans, M. J., Knauff, E. A. H., Westerveld, H. E., Fauser, B. C. J. M., & Broekmans, F. J. (2008) · Human Reproduction · doi:10.1093/humrep/den433 · Cited by 135 · see citing works
Cardiovascular risk factors and ultrasound evaluation of intima-media thickness at common carotids, carotid bulbs, and femoral and abdominal aorta arteries in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Sartorato, P., Zulian, E., Benedini, S., Mariniello, B., Schiavi, F., Bilora, F., Pozzan, G., Greggio, N., Pagnan, A., Mantero, F., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1711 · Cited by 132 · see citing works
Anti-Hypertensive Effect of γ-Aminobutyric Acid (GABA)-Rich<i>Chlorella</i>on High-Normal Blood Pressure and Borderline Hypertension in Placebo-Controlled Double Blind Study
Shimada, M., Hasegawa, T., Nishimura, C., Kan, H., Kanno, T., Nakamura, T., & Matsubayashi, T. (2009) · Clinical and Experimental Hypertension · doi:10.1080/10641960902977908 · Cited by 124 · see citing works
Relationship of Adolescent Polycystic Ovary Syndrome to Parental Metabolic Syndrome
Leibel, N. I., Baumann, E. E., Kocherginsky, M., & Rosenfield, R. L. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1707 · Cited by 118 · see citing works
Effects of Exercise on Lipoprotein Particles in Women with Polycystic Ovary Syndrome
BROWN, A. J., SETJI, T. L., SANDERS, L. L., LOWRY, K. P., OTVOS, J. D., KRAUS, W. E., & SVETKEY, P. L. (2009) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e31818c6c0c · Cited by 101 · see citing works
Inositols in PCOS
Kamenov, Z., & Gateva, A. (2020) · Molecules · doi:10.3390/molecules25235566 · Cited by 100 · see citing works
Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome
Sam, S., & Ehrmann, D. A. (2017) · Diabetologia · doi:10.1007/s00125-017-4306-3 · Cited by 93 · see citing works
Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome
Donà, G., Sabbadin, C., Fiore, C., Bragadin, M., Giorgino, F. L., Ragazzi, E., Clari, G., Bordin, L., & Armanini, D. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0840 · Cited by 89 · see citing works
Mechanisms IN endocrinology: metabolic syndrome through the female life cycle
Vryonidou, A., Paschou, S. A., Muscogiuri, G., Orio, F., & Goulis, D. G. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0275 · Cited by 88 · see citing works
Genetic variation in 11β-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome
Gambineri, A., Vicennati, V., Genghini, S., Tomassoni, F., Pagotto, U., Pasquali, R., & Walker, B. R. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2222 · Cited by 75 · see citing works
Young women's experiences living with polycystic ovary syndrome
Weiss, T. R., & Bulmer, S. M. (2011) · Journal of Obstetric, Gynecologic & Neonatal Nursing · doi:10.1111/j.1552-6909.2011.01299.x · Cited by 73 · see citing works
Polycystic Ovarian Syndrome: Long-Term Health Consequences
Zore, T., Joshi, N., Lizneva, D., & Azziz, R. (2017) · Seminars in Reproductive Medicine · doi:10.1055/s-0037-1603096 · Cited by 72 · see citing works
Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced?
Tomlinson, J., Millward, A., Stenhouse, E., & Pinkney, J. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.02994.x · Cited by 66 · see citing works
Prevalence of the metabolic syndrome in women with a previous diagnosis of polycystic ovary syndrome: long-term follow-up
Hudecova, M., Holte, J., Olovsson, M., Larsson, A., Berne, C., & Sundstrom-Poromaa, I. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.08.006 · Cited by 61 · see citing works
Disordered Eating Behaviours and Eating Disorders in Women in Australia with and Without Polycystic Ovary Syndrome: A Cross-Sectional Study
Pirotta, S., Barillaro, M., Brennan, L., Grassi, A., Jeanes, Y., Joham, A., Kulkarni, J., Couch, L., Lim, S., & Moran, L. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101682 · Cited by 52 · see citing works
Use of metformin in the treatment of polycystic ovary syndrome
Genazzani, A. D., Ricchieri, F., & Lanzoni, C. (2010) · Women's Health · doi:10.2217/whe.10.43 · Cited by 51 · see citing works
Myo-inositol administration positively effects ovulation induction and intrauterine insemination in patients with polycystic ovary syndrome: a prospective, controlled, randomized trial
Emekçi Özay, Ö., Özay, A. C., Çağlıyan, E., Okyay, R. E., & Gülekli, B. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1296127 · Cited by 49 · see citing works
Is there a dose-response relationship of metformin treatment in patients with polycystic ovary syndrome? Results from a multicentric study
Fulghesu, A. M., Romualdi, D., Di Florio, C., Sanna, S., Tagliaferri, V., Gambineri, A., Tomassoni, F., Minerba, L., Pasquali, R., & Lanzone, A. (2012) · Human Reproduction · doi:10.1093/humrep/des262 · Cited by 48 · see citing works
Effects of testosterone and estrogen treatment on lipolysis signaling pathways in subcutaneous adipose tissue of postmenopausal women
Zang, H., Rydén, M., Wåhlen, K., Dahlman-Wright, K., Arner, P., & Hirschberg, A. L. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.11.088 · Cited by 47 · see citing works
Adverse pregnancy conditions, infertility, and future cardiovascular risk: implications for mother and child
Park, K., Wei, J., Minissian, M., Bairey Merz, C. N., & Pepine, C. J. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6597-2 · Cited by 40 · see citing works
The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome: PCOS, NAFLD and metformin therapy
Preiss, D., Sattar, N., Harborne, L., Norman, J., & Fleming, R. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01825.x · Cited by 39 · see citing works
Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor
Marinkovic-Radosevic, J., Cigrovski Berkovic, M., Kruezi, E., Bilic-Curcic, I., & Mrzljak, A. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i7.932 · Cited by 35 · see citing works
Obesity and the Risk of Infertility, Gestational Diabetes, and Type 2 Diabetes in Polycystic Ovary Syndrome
Pirotta, S., Joham, A., Grieger, J. A., Tay, C. T., Bahri-Khomami, M., Lujan, M., Lim, S. S., & Moran, L. J. (2020) · Seminars in Reproductive Medicine · doi:10.1055/s-0041-1726866 · Cited by 29 · see citing works
Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?
Pugliese, G., de Alteriis, G., Muscogiuri, G., Barrea, L., Verde, L., Zumbolo, F., Colao, A., & Savastano, S. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02084-6 · Cited by 29 · see citing works
Evaluation of insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome
Lankarani, M., Valizadeh, N., Heshmat, R., Peimani, M., & Sohrabvand, F. (2009) · Gynecological Endocrinology · doi:10.1080/09513590902972083 · Cited by 25 · see citing works
Metabolomic Biomarkers in Polycystic Ovary Syndrome: A Review of the Evidence
Alesi, S., Ghelani, D., & Mousa, A. (2021) · Seminars in Reproductive Medicine · doi:10.1055/s-0041-1729841 · Cited by 16 · see citing works
Pancreatic β-cell dysfunction in polycystic ovary syndrome: the role of metformin
Messer, C., Boston, R., Leroith, D., Geer, E., Miller, J. D., Messer, M., & Futterweit, W. (2012) · Endocrine Practice · doi:10.4158/ep11375.or · Cited by 16 · see citing works
Evaluation of potential association of metabolic syndrome in obese and non-obese PCOS women
Kaur, R., & Kaur, M. (2024) · Middle East Fertility Society Journal · doi:10.1186/s43043-024-00170-0 · Cited by 2 · see citing works

Hyperinsulinemia and acanthosis nigricans in African Americans.
Stuart, C. A., Gilkison, C. R., Keenan, B. S., et al. (1997) · PubMed · Cited by 36 · see citing works
The contribution of hyperinsulinemia to the hyperandrogenism of polycystic ovary syndrome
Pateguana, N. B., & Janes, A. N. (2019) · Journal of Metabolic Health · doi:10.4102/jir.v4i1.50 · Cited by 17 · see citing works
Is Hyperinsulinemia the Cause of Acanthosis Nigricans in the Type B Syndrome of Insulin Resistance?
Eriksson, J. W. (1997) · Diabetes Care · doi:10.2337/diacare.20.6.1045a · Cited by 4 · see citing works
The central role of obesity (hyperinsulinemia) in the pathogenesis of the polycystic ovary syndrome
Nestler, J. E., Clore, J. N., & Blackard, W. G. (1989) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(89)90640-6 · Cited by 103 · see citing works
Self-citation
The dermatologic manifestation of hyperandrogenism: A retrospective chart review
Clark, C. M., Rudolph, J. L., Gerber, D. A., et al. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.09.184 · Cited by 14 · see citing works

Authors: Apridonidze, T., Essah, P. A., Iuorno, M. J., & Nestler, J. E.
Affiliations: Departments of Internal Medicine (T.A., P.A.E., M.J.I., J.E.N.) Richmond, Virginia 23298-0111
Virginia Commonwealth University (US)
Corresponding author: Nestler, John E.
Venue: The Journal of Clinical Endocrinology & Metabolism
Publisher: The Endocrine Society
Published: 2005-04-01
Volume: 90
Issue: 4
Pages: 1929-1935
ISSN: 0021-972X (ISSN-L)
1945-7197
DOI: 10.1210/jc.2004-1045
OpenAlex: W2095810284
Cited by: 931
References: 45
Citations by year: 2026: 14 · 2025: 31 · 2024: 35 · 2023: 27 · 2022: 28 · 2021: 42 · 2020: 28 · 2019: 42 · 2018: 29 · 2017: 43 · 2016: 38 · 2015: 63 · 2014: 42 · 2013: 53 · 2012: 54
FWCI: 65.82
Type: journal article
Language: en
Open access: closed
Locations: The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute on Drug Abuse (DA-14041-03, K12DA014041)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (K24HD040237)
Topics: Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
Keywords: polycystic ovary syndrome, metabolic syndrome, insulin resistance, hyperinsulinemia, hyperandrogenism, acanthosis nigricans, sex hormone-binding globulin, free testosterone, menstrual irregularity, cardiovascular risk, prevalence
MeSH terms: Adult, Age Factors, Aged, Female, Humans, Cholesterol, HDL, Middle Aged, Polycystic Ovary Syndrome, Retrospective Studies, Sex Hormone-Binding Globulin, Testosterone, Body Mass Index, Prevalence, Glucose Intolerance, Metabolic Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prevalence and Characteristics of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks